Cargando…
Iterative Structure-Based Peptide-Like Inhibitor Design against the Botulinum Neurotoxin Serotype A
The botulinum neurotoxin serotype A light chain (BoNT/A LC) protease is the catalytic component responsible for the neuroparalysis that is characteristic of the disease state botulism. Three related peptide-like molecules (PLMs) were designed using previous information from co-crystal structures, sy...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2894858/ https://www.ncbi.nlm.nih.gov/pubmed/20614028 http://dx.doi.org/10.1371/journal.pone.0011378 |
_version_ | 1782183228596027392 |
---|---|
author | Zuniga, Jorge E. Hammill, Jared T. Drory, Omri Nuss, Jonathan E. Burnett, James C. Gussio, Rick Wipf, Peter Bavari, Sina Brunger, Axel T. |
author_facet | Zuniga, Jorge E. Hammill, Jared T. Drory, Omri Nuss, Jonathan E. Burnett, James C. Gussio, Rick Wipf, Peter Bavari, Sina Brunger, Axel T. |
author_sort | Zuniga, Jorge E. |
collection | PubMed |
description | The botulinum neurotoxin serotype A light chain (BoNT/A LC) protease is the catalytic component responsible for the neuroparalysis that is characteristic of the disease state botulism. Three related peptide-like molecules (PLMs) were designed using previous information from co-crystal structures, synthesized, and assayed for in vitro inhibition against BoNT/A LC. Our results indicate these PLMS are competitive inhibitors of the BoNT/A LC protease and their K(i) values are in the nM-range. A co-crystal structure for one of these inhibitors was determined and reveals that the PLM, in accord with the goals of our design strategy, simultaneously involves both ionic interactions via its P1 residue and hydrophobic contacts by means of an aromatic group in the P2′ position. The PLM adopts a helical conformation similar to previously determined co-crystal structures of PLMs, although there are also major differences to these other structures such as contacts with specific BoNT/A LC residues. Our structure further demonstrates the remarkable plasticity of the substrate binding cleft of the BoNT/A LC protease and provides a paradigm for iterative structure-based design and development of BoNT/A LC inhibitors. |
format | Text |
id | pubmed-2894858 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-28948582010-07-07 Iterative Structure-Based Peptide-Like Inhibitor Design against the Botulinum Neurotoxin Serotype A Zuniga, Jorge E. Hammill, Jared T. Drory, Omri Nuss, Jonathan E. Burnett, James C. Gussio, Rick Wipf, Peter Bavari, Sina Brunger, Axel T. PLoS One Research Article The botulinum neurotoxin serotype A light chain (BoNT/A LC) protease is the catalytic component responsible for the neuroparalysis that is characteristic of the disease state botulism. Three related peptide-like molecules (PLMs) were designed using previous information from co-crystal structures, synthesized, and assayed for in vitro inhibition against BoNT/A LC. Our results indicate these PLMS are competitive inhibitors of the BoNT/A LC protease and their K(i) values are in the nM-range. A co-crystal structure for one of these inhibitors was determined and reveals that the PLM, in accord with the goals of our design strategy, simultaneously involves both ionic interactions via its P1 residue and hydrophobic contacts by means of an aromatic group in the P2′ position. The PLM adopts a helical conformation similar to previously determined co-crystal structures of PLMs, although there are also major differences to these other structures such as contacts with specific BoNT/A LC residues. Our structure further demonstrates the remarkable plasticity of the substrate binding cleft of the BoNT/A LC protease and provides a paradigm for iterative structure-based design and development of BoNT/A LC inhibitors. Public Library of Science 2010-06-30 /pmc/articles/PMC2894858/ /pubmed/20614028 http://dx.doi.org/10.1371/journal.pone.0011378 Text en Zuniga et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Zuniga, Jorge E. Hammill, Jared T. Drory, Omri Nuss, Jonathan E. Burnett, James C. Gussio, Rick Wipf, Peter Bavari, Sina Brunger, Axel T. Iterative Structure-Based Peptide-Like Inhibitor Design against the Botulinum Neurotoxin Serotype A |
title | Iterative Structure-Based Peptide-Like Inhibitor Design against the Botulinum Neurotoxin Serotype A |
title_full | Iterative Structure-Based Peptide-Like Inhibitor Design against the Botulinum Neurotoxin Serotype A |
title_fullStr | Iterative Structure-Based Peptide-Like Inhibitor Design against the Botulinum Neurotoxin Serotype A |
title_full_unstemmed | Iterative Structure-Based Peptide-Like Inhibitor Design against the Botulinum Neurotoxin Serotype A |
title_short | Iterative Structure-Based Peptide-Like Inhibitor Design against the Botulinum Neurotoxin Serotype A |
title_sort | iterative structure-based peptide-like inhibitor design against the botulinum neurotoxin serotype a |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2894858/ https://www.ncbi.nlm.nih.gov/pubmed/20614028 http://dx.doi.org/10.1371/journal.pone.0011378 |
work_keys_str_mv | AT zunigajorgee iterativestructurebasedpeptidelikeinhibitordesignagainstthebotulinumneurotoxinserotypea AT hammilljaredt iterativestructurebasedpeptidelikeinhibitordesignagainstthebotulinumneurotoxinserotypea AT droryomri iterativestructurebasedpeptidelikeinhibitordesignagainstthebotulinumneurotoxinserotypea AT nussjonathane iterativestructurebasedpeptidelikeinhibitordesignagainstthebotulinumneurotoxinserotypea AT burnettjamesc iterativestructurebasedpeptidelikeinhibitordesignagainstthebotulinumneurotoxinserotypea AT gussiorick iterativestructurebasedpeptidelikeinhibitordesignagainstthebotulinumneurotoxinserotypea AT wipfpeter iterativestructurebasedpeptidelikeinhibitordesignagainstthebotulinumneurotoxinserotypea AT bavarisina iterativestructurebasedpeptidelikeinhibitordesignagainstthebotulinumneurotoxinserotypea AT brungeraxelt iterativestructurebasedpeptidelikeinhibitordesignagainstthebotulinumneurotoxinserotypea |